Animal Parasiticides Market Report

• Zoetis Inc (United States) received conditional approval from the US FDA for Dectomax®-CA1 Injectable, making it the first and only product approved for treating and preventing infestations caused by New World screwworm larvae (Cochliomyia hominivorax) in various cattle categories, including prevention of reinfestation for 21 days. The product is expected to be available in early 2026. (September 30, 2025)

• MERCK & CO., INC. (MSD ANIMAL HEALTH) (US) presented multiple studies at the 2025 WAAVP Congress showcasing the efficacy and safety of its BRAVECTO® portfolio for dogs, including the injectable BRAVECTO 365 for fleas, ticks, and mites (lasting 365 days), and the oral BRAVECTO 1 MONTH TRIPLE for demodectic mange, intestinal worms, and heartworm prevention, highlighting the company’s commitment to parasite treatment and prevention research. (August 18, 2025)

Drivers: Increasing pet humanization and ownership

The rising trend of pet humanization, where companion animals are increasingly viewed as family members, is a significant driver for the parasiticides market. This shift in perspective has led to higher expenditure on preventive veterinary care, including regular parasite control. According to the American Pet Products Association (APPA), in 2023, around 66% of US homes—or over 85 million families—owned a pet. This high rate of pet ownership, combined with increased spending on health and wellness, fuels a robust demand for parasiticides.
Furthermore leading animal health companies like Zoetis and Boehringer Ingelheim have responded by expanding their companion animal product portfolios, including launching innovative broad-spectrum chewable tablets and topical solutions. These products cater to owners’ preferences for convenient, effective treatments and help improve compliance with regular parasite prevention protocols.

Opportunities: Growth in emerging markets for livestock production

Emerging markets, particularly in the Asia-Pacific and Latin America regions, offer a major opportunity due to the expanding livestock industry and rising demand for animal protein. The Food and Agriculture Organization (FAO) of the United Nations projects that the global population will reach 9.7 billion by 2050, driving a significant increase in demand for animal products. This compels livestock producers to adopt advanced veterinary practices to maintain animal health and maximize productivity.
For instance, a January 2024 study by Brazil’s Oswaldo Cruz Institute highlighted the discovery of new parasites in aquaculture, emphasizing the need for effective parasiticides to protect livestock fish. Companies are capitalizing on this need; in September 2023, the Bill & Melinda Gates Foundation partnered with Boehringer Ingelheim to combat African animal trypanosomiasis in sub-Saharan Africa, a region with a large cattle population.

Challenges: Growing antimicrobial resistance (AMR) and stringent regulation

The increasing prevalence of antimicrobial resistance (AMR) in animals poses a significant challenge, threatening the effectiveness of existing parasiticides. Overuse and misuse of these drugs can lead to the emergence of multi-drug-resistant parasites, necessitating costly and time-consuming research for new solutions. For example, the Indian Council of Agricultural Research (ICAR) initiated the All-India Network Programme on AMR (AINP-AMR) involving over 31 centers to monitor and surveil AMR in food animals, demonstrating the government’s concern. This challenge is compounded by increasingly stringent regulatory environments, such as those overseen by the US Food and Drug Administration (FDA). The extensive testing and robust clinical trials required for product approval increase the cost and time to market for new drugs. In April 2025, the U.S. government introduced new tariffs on imported active pharmaceutical ingredients, further adding to the complexity for manufacturers.

The global animal parasiticides market is a critical segment within the broader animal health industry, playing a vital role in protecting the health and productivity of companion animals and livestock by preventing and treating parasitic infestations. Valued at USD 11.2 billion in 2024, the animal parasiticides market is projected to reach around USD 15.8 billion by 2030, reflecting a CAGR of 6 % during the forecast period.
This growth is driven by increasing pet ownership and humanization trends, rising awareness of livestock health’s economic impact, and the growing global demand for animal protein. The livestock sector remains a major contributor, with high demand for parasiticides to control diseases affecting cattle, sheep, and pigs, while the companion animal segment is expanding significantly due to higher spending on pet healthcare and preventative treatments.